OIPE
JAN 26 2007
PATENT & TRADEMARK OFFICE

BEST AVAILABLE COPY

PTO/SB/08b (06-03)
Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | | of | |

Complete If Known	
Application Number	
Filing Date	
First Named Inventor	
Art Unit	
Examiner Name	
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	ARUN K. GHOSH ET AL., "Stereoselective reduction of α-hydroxy oxime ethers: a convenient route to cis-1,2 amino alcohols", Tetrahedron Letters, 1991, p. 711-714	
	2	BARBARA A. WAY ET AL, "Isotope dilution GC-MS measurement of tricyclic antidepressant drugs. Utility of 4-carbethoxyhexafluorobutyryl derivatives of secondary amines", Journal of Analytical Toxicology, Sep/1998, p. 374-382, vol. 22.	
	3	DENNIS J. DIETZEN ET AL, "Facilitation of thin-layer chromatographic identification of opiates by derivatization with acetic anhydride and or methoxyamine", Journal of Analytical Toxicology, Sep 1995, p. 299-303, vol 19.	
	4	DONG-LIANG-LIN ET AL, "Chemical derivatization and the selection of deuterated internal standard for quantitative determination - methamphetamine example", Journal of Analytical Toxicology, May/June 2000, p. 275-280, vol 24.	
	5	HIDEYUKI YAMADA ET AL, "Dansyl chloride derivatization of methamphetamine: a method with advantages for screening and analysis of methamphetamine in urine", Journal of Analytical Toxicology, Jan/Feb 2002, p. 17-22, vol 19.	
	6	HIROSHI GODA ET AL, "Facile synthesis of 5-substituted-2-acylthiophenes", Synthesis, 1992, p. 849-851	
	7	J. G. GUILLOT ET AL, "Determination of heroine, 6-acetylmorphine, and morphine in biological fluids using their propyl derivatives	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

PTO/SB/08b (06-03)
Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | | of | |

Complete If Known	
Application Number	
Filing Date	
First Named Inventor	
Art Unit	
Examiner Name	
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	7 cont't	with ion trap GC-MS", Journal of Analytical Toxicology, March/April 1997, p. 127-133, vol 21.	
	8	JENS PIETZSCH ET AL," Rapid determination of total homocystine in human plasma by using N(O,S)-Ethoxy carbonyl ethyl ester derivatives and GC-MS", Clinical Chemistry, 1997, p. 2001-2004, vol 43(10).	
	9	KENJI HARA ET AL," Simple extractive derivatization of methamphetamine and its metabolites in biological materials with enclosed columns for their GC-MS determination", Journal of Analytical Toxicology, Jan/Feb 1997, p. 54-58, vol. 21.	
	10	KYLE R. GEE ET AL," Acute chronic and manganese tricarbonyl analogs of the PCP receptor ligands 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5,10-imine (MK-801) and 10,5-(iminomethano)-10,11-dihydro-5H-dibenzo[a,d],cycloheptene", Journal of Organic Chemistry, 1994, p. 1492-1498, vol 59	
	11	MACIEJ BOGUSZ ET AL," Analysis of underivatized amphetamines and related phenethylamines with HPLC-APCI-MS", Journal of Analytical Toxicology, March 2000, p. 77-84, vol 24.	
	12	MACIEJ BOGUSZ," Determination of phenylisocyanate derivatives of amphetamine and its analogs in biological fluids by HPLC-APCI-MS or DAD", Journal of Analytical Toxicology, Jan 1997, p 59-69, vol 21.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

PTO/SB/08b (06-03)
Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | | of | |

Complete If Known	
Application Number	
Filing Date	
First Named Inventor	
Art Unit	
Examiner Name	
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	13	MARK M. KUSHMIR ET AL," Comparison of four derivatizing reagents for 6-acetylmorphine GC-MS analysis", Journal of Analytical Toxicology, July/Aug 1999, p. 262-269, vol 23.	
	14	MICHAEL L. SMITH ET AL," Forensic drug testing for opiates. VI. Urine testing for hydromorphone, hydrocodone, oxymorphone, and oxycodone with commercial opiate immunoassay and GC-MS", Journal of Analytical Toxicology, Jan/Feb 1995, p. 18-26, vol 19.	
	15	NIEVES PIZARRO ET AL," Determination of MDMA and its metabolites in blood and urine by GC-MS and analysis of enantiomers by capillary electrophoresis", Journal of Analytical Toxicology, April 2002, p. 157-165, vol 26.	
	16	P. DALLAKIAN ET AL," Detection and quantitation of amphetamine and methamphetamine : EI and CI with ammonia-comparative investigation on Shimadzu QP5000 GC-MS System", Journal of Analytical Toxicology, July/Aug 1996, p. 255-261, vol 20.	
	17	PETR HUSEK AND PETR SIMEK," Advances in amino acid analysis", LCGC Sep. 2001, p. 986-999, vol 19.	
	18	PETR HUSEK," Chloroformates in GC as general purpose derivatizing agents", Journal of Chromatography B, 1998, p 57-91, vol 717.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

PTO/SB/08b (06-03)
Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | | of | |

Complete If Known	
Application Number	
Filing Date	
First Named Inventor	
Art Unit	
Examiner Name	
Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	19	PING CAO AND MEHDI MOINI, "Quantitative analysis of fluorinated ethylchloroformate derivatives of protein amino acids and hydrolysis products of small peptides using chemical ionization GC-MS," Journal of Chromatography A, 1997, p. 117-127, vol 759.	
	20	ROBERT MEATHERALL, "Rapid GC-MS confirmation of urinary amphetamine and methamphetamine as their propyl-chloroformate derivatives," Journal of Analytical Toxicology, Sep 1995, p. 316-322, vol. 19.	
	21	WILLIAM A JOERN, "Unexpected volatility of barbiturate derivatives: an extractive alkylation procedure for barbiturates and benzoylecgonine," Journal of Analytical Toxicology, Nov 1994, p. 423, vol 18.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.